Abstract:Abstract Background Neuronal accumulation of misfolded microtubule-associated protein tau is a hallmark of neuropathology in Alzheimer’s disease, frontotemporal dementia, and other tauopathies, and has been a therapeutic target. Microglia can spread tau pathology by secreting tau-containing exosomes, although the specific molecular target is yet to be identified for the therapeutic intervention. P2X purinoceptor 7 (P2RX7) is an ATP-gated cation channel, enriched in microglia and triggers exosome secretion. The purpose of the study is to examine the therapeutic effect of an orally applicable, CNS-penetrant P2RX7 specific inhibitor on the early disease stage of a tauopathy mouse model. Methods Three-months-old P301S tau mice were treated with P2RX7-specific inhibitor GSK1482160 or vehicle for 30 days, followed by behavioral, biochemical and immunohistochemical assessment. GSK1482160 was also tested for exosome secretion from primary cultured murine astrocytes, neurons and microglia in vitro. Results Oral administration of GSK1482160 significantly reduced accumulation of MC1 + and Alz50 + misfolded tau in hippocampal regions, which was accompanied with reduced accumulation of Tsg101, an exosome marker, in hippocampal neurons. Proximity ligation assay demonstrated complex formation of Alz50 + tau and Tsg101 in hippocampal neurons, which was reduced by GSK1482160. On the other hand, GSK1482160 had no effect on microglial ramification or CD68 expression, which was significantly enhanced in P301S mice, or pro/anti-inflammatory cytokine gene expression. Strikingly, GSK1482160-treated P301S mice show significantly improved working and contextual memory as determined by Y-maze and fear conditioning tests. GSK1482160 also significantly increased accumulation of Tsg101 and CD81 in microglia in vivo , suggesting its suppression of P2RX7-induced exosome secretion from microglia . This effect was confirmed in vitro, as ATP-induced secretion of tau-containing exosome was significantly suppressed by GSK1482160 treatment from primary murine microglia, but not from neurons or astrocytes. Discussion The oral administration of P2RX7 inhibition mitigates disease phenotypes in P301S mice, likely by suppressing release of microglial exosomes. P2RX7 could be a novel therapeutic target for the early stage tauopathy development.

Silencing of the P2X(7) Receptor Enhances Amyloid-Β Phagocytosis by Microglia.

[Effects of RNA Interference Targeting P2X7 Receptor on Microglial Phagocytosis of Amyloid-Β Protein].

RNA interference silencing P2X7 receptor restrained inflammatory factors released from the microglia

P2X receptor overexpression induced by soluble oligomers of amyloid beta peptide potentiates synaptic failure and neuronal dyshomeostasis in cellular models of Alzheimer's disease

IL-1RA Disrupts ATP Activation of P2RX7 in Human Monocyte-Derived Microglia-like Cells

P2X7 Receptor is Critical in Α-Synuclein–mediated Microglial NADPH Oxidase Activation

Interferon Regulatory Factor 5 Regulates the Phagocytosis of Microglia and Alleviate Alzheimer's Pathology.

Microglial P2X4 receptors promote ApoE degradation and contribute to memory deficits in Alzheimer's disease

Inhibition of P2X7 Receptor Ameliorates Transient Global Cerebral Ischemia/reperfusion Injury Via Modulating Inflammatory Responses in the Rat Hippocampus

Silencing of long noncoding RNA X-inactive specific transcript alleviates Aβ1-42-induced microglia-mediated neurotoxicity by shifting microglial M1/M2 polarization

The P38 Mitogen Activated Protein Kinase Regulates Β-Amyloid Protein Internalization Through the Α7 Nicotinic Acetylcholine Receptor in Mouse Brain.

P2RX7 inhibitor suppresses exosome secretion and disease phenotype in P301S tau transgenic mice

P2X7 receptor signaling pathway as a therapeutic target for neurodegenerative diseases

The P2X7 Receptor, a Multifaceted Receptor in Alzheimer's Disease

The Role of P2X7R in Neuroinflammation and Implications in Alzheimer's Disease.

P2X7R influences tau aggregate burden in human tauopathies and shows distinct signalling in microglia and astrocytes

Presenilin 2 deficiency facilitates Aβ-induced neuroinflammation and injury by upregulating P2X7 expression

P2Y4 receptor-mediated pinocytosis contributes to amyloid beta-induced self-uptake by microglia.

Revealing the Novel Role of Purinergic Receptor P2X4 in Phagocytic Uptake After Ischemic Stroke

Activation of Α7 Nicotinic Acetylcholine Receptor Alleviates Aβ1-42-induced Neurotoxicity Via Downregulation of P38 and JNK MAPK Signaling Pathways.

Microglial purinergic signaling in Alzheimer's disease